首页> 外文期刊>Antimicrobial agents and chemotherapy. >'Slow VISA,' a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate staphylococcus aureus strain Mu3
【24h】

'Slow VISA,' a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate staphylococcus aureus strain Mu3

机译:“慢速VISA”,一种新的万古霉素耐药表型,在异源万古霉素中间金黄色葡萄球菌菌株Mu3中体外发现

获取原文
获取原文并翻译 | 示例
           

摘要

Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) clinical strain Mu3 spontaneously generates VISA strains at an extremely high frequency (≥1 × 10-6). The generated VISA strains usually grow more slowly than does the parent hVISA strain, but they form colonies on vancomycin-containing agar plates before 48 h of incubation. However, we noticed a curious group of VISA strains, designated "slow VISA" (sVISA), whose colonies appear only after 72 h of incubation. They have extremely prolonged doubling times but have vancomycin MICs of 8 to ~24 mg/liter when determined after 72 to ~144 h of incubation. We established strain Mu3-6R-P (6R-P), which has a vancomycin MIC of 16 mg/liter (at 72 h), as a representative sVISA strain. Its cell wall was thickened and autolytic activity was decreased compared to the respective qualities of the parent hVISA strain Mu3. Whole-genome sequencing of 6R-P revealed only one mutation, encoded by rpoB (R512P), which replaced the 512th arginine of the RNA polymerase β-subunit with proline. Its VISA phenotype was unstable, and the strain frequently reverted to hVISA with concomitant losses of pinpoint colony morphology and cell wall thickness and reduced autolytic activity. Sequencing of the rpoB genes of the phenotypic revertant strains revealed mutations affecting the 512th codon, where the proline of 6R-P was replaced with leucine, serine, or histidine. Slow VISA generated in the tissues of an infected patient serves as a temporary shelter for hVISA to survive vancomycin therapy. The sVISA strain spontaneously returns to hVISA when the threat of vancomycin is lifted. The rpoB(R512P) mutation may be regarded as a regulatory mutation that switches the reversible pheno-type of sVISA on and off.
机译:万古霉素中间体金黄色葡萄球菌(hVISA)临床菌株Mu3自发地以极高的频率(≥1×10-6)产生VISA菌株。产生的VISA菌株通常比亲代hVISA菌株生长更慢,但是在培养48小时之前它们会在含有万古霉素的琼脂平板上形成菌落。但是,我们注意到一组奇怪的VISA菌株,称为“慢VISA”(sVISA),其菌落仅在孵育72小时后出现。它们具有极长的倍增时间,但在孵育72至144小时后测定的万古霉素MIC为8至〜24 mg / L。我们建立了具有代表性的sVISA菌株Mu3-6R-P(6R-P),万古霉素的MIC为16 mg / L(72小时)。与亲本hVISA菌株Mu3的相应品质相比,其细胞壁增厚并且自溶活性降低。对6R-P进行全基因组测序仅显示了一个由rpoB(R512P)编码的突变,该突变用脯氨酸代替了RNA聚合酶β亚基的512位精氨酸。它的VISA表型是不稳定的,并且该菌株经常回复到hVISA,伴随着精确的集落形态和细胞壁厚度的损失以及自溶活性的降低。表型回复株的rpoB基因的测序揭示了影响第512个密码子的突变,其中6R-P的脯氨酸被亮氨酸,丝氨酸或组氨酸取代。在感染患者组织中产生的缓慢的VISA可作为hVISA在万古霉素治疗中存活的临时庇护所。当万古霉素的威胁解除时,sVISA菌株自发地返回hVISA。 rpoB(R512P)突变可被视为调节性突变,可打开和关闭sVISA的可逆表型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号